The global CSF biosimilars market is expected to grow at a CAGR of 16.2% during the forecast period, from 2021 to 2030. The growth of this market can be attributed to the increasing demand for cost-effective and affordable drugs, which are also safe and effective. The major factors driving the growth of this market are increasing prevalence of chronic diseases, rising healthcare expenditure in emerging economies, and growing awareness about biosimilars among physicians and patients. However, stringent regulatory requirements for approval may restrain the growth of this market in some regions such as North America.
The human growth hormone segment is expected to lead the global CSF biosimilars market during the forecast period owing to its high prevalence among patients with chronic diseases such as diabetes mellitus type 2 (DM2). The erythropoietin segment is projected to grow at a CAGR of 17% during 2021-2030 due to its high prevalence among patients with blood disorders such as anemia or leukemia.
Some Of The Growth Factors Of This Market:
- The increasing prevalence of chronic diseases such as cancer and diabetes is driving the growth of the global G-CSF biosimilars market.
- Increasing awareness about the benefits of biosimilars among healthcare providers and patients is also driving the growth of this market globally.
- The high cost associated with biologics has been a major factor for their adoption in emerging markets such as India and China which are witnessing an increase in disposable income levels over time and are expected to drive demand for these products in these countries during the forecast period (2018-2023) 5) Increasing government initiatives for promoting biosimilar drugs will also fuel this market's growth globally.
Industry Growth Insights published a new data on “G-CSF Biosimilars Market”. The research report is titled “G-CSF Biosimilars Market research by Types (Human Growth Hormone, Erythropoietin, Monoclonal Antibodies, Insulin, Interferon, Granulocyte-Colony Stimulating Factor), By Applications (Blood Disorders, Oncology Diseases, Chronic And Autoimmune Diseases, Growth Hormone Deficiencies), By Players/Companies Pfizer, Novartis, Roche, Merck & Co., Sanofi, Johnson & Johnson, Gilead Science, GlaxoSmithKline, AbbVie, Amgen, AstraZeneca, Bayer”.
Scope Of The Report
Report Attributes
Report Details
Report Title
G-CSF Biosimilars Market Research Report
By Type
Human Growth Hormone, Erythropoietin, Monoclonal Antibodies, Insulin, Interferon, Granulocyte-Colony Stimulating Factor
By Application
Blood Disorders, Oncology Diseases, Chronic And Autoimmune Diseases, Growth Hormone Deficiencies
By Companies
Pfizer, Novartis, Roche, Merck & Co., Sanofi, Johnson & Johnson, Gilead Science, GlaxoSmithKline, AbbVie, Amgen, AstraZeneca, Bayer
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
242
Number of Tables & Figures
170
Customization Available
Yes, the report can be customized as per your need.
Global G-CSF Biosimilars Market Report Segments:
The global G-CSF Biosimilars market is segmented on the basis of:
Types
Human Growth Hormone, Erythropoietin, Monoclonal Antibodies, Insulin, Interferon, Granulocyte-Colony Stimulating Factor
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Blood Disorders, Oncology Diseases, Chronic And Autoimmune Diseases, Growth Hormone Deficiencies
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- Novartis
- Roche
- Merck & Co.
- Sanofi
- Johnson & Johnson
- Gilead Science
- GlaxoSmithKline
- AbbVie
- Amgen
- AstraZeneca
- Bayer
Highlights of The G-CSF Biosimilars Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Human Growth Hormone
- Erythropoietin
- Monoclonal Antibodies
- Insulin
- Interferon
- Granulocyte-Colony Stimulating Factor
- By Application:
- Blood Disorders
- Oncology Diseases
- Chronic And Autoimmune Diseases
- Growth Hormone Deficiencies
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the G-CSF Biosimilars Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
G-CSF biosimilars are a type of biologic drug that is similar to the original G-CSF. Biosimilars are made from a different protein than the original G-CSF, but they still work in the same way and have the same benefits as regular G-CSF.
Some of the key players operating in the g-csf biosimilars market are Pfizer, Novartis, Roche, Merck & Co., Sanofi, Johnson & Johnson, Gilead Science, GlaxoSmithKline, AbbVie, Amgen, AstraZeneca, Bayer.
The g-csf biosimilars market is expected to register a CAGR of 16.2%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. G-CSF Biosimilars Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. G-CSF Biosimilars Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. G-CSF Biosimilars Market - Supply Chain
4.5. Global G-CSF Biosimilars Market Forecast
4.5.1. G-CSF Biosimilars Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. G-CSF Biosimilars Market Size (000 Units) and Y-o-Y Growth
4.5.3. G-CSF Biosimilars Market Absolute $ Opportunity
5. Global G-CSF Biosimilars Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. G-CSF Biosimilars Market Size and Volume Forecast by Type
5.3.1. Human Growth Hormone
5.3.2. Erythropoietin
5.3.3. Monoclonal Antibodies
5.3.4. Insulin
5.3.5. Interferon
5.3.6. Granulocyte-Colony Stimulating Factor
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global G-CSF Biosimilars Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. G-CSF Biosimilars Market Size and Volume Forecast by Application
6.3.1. Blood Disorders
6.3.2. Oncology Diseases
6.3.3. Chronic And Autoimmune Diseases
6.3.4. Growth Hormone Deficiencies
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global G-CSF Biosimilars Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. G-CSF Biosimilars Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global G-CSF Biosimilars Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. G-CSF Biosimilars Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global G-CSF Biosimilars Demand Share Forecast, 2019-2029
9. North America G-CSF Biosimilars Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America G-CSF Biosimilars Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America G-CSF Biosimilars Market Size and Volume Forecast by Application
9.4.1. Blood Disorders
9.4.2. Oncology Diseases
9.4.3. Chronic And Autoimmune Diseases
9.4.4. Growth Hormone Deficiencies
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America G-CSF Biosimilars Market Size and Volume Forecast by Type
9.7.1. Human Growth Hormone
9.7.2. Erythropoietin
9.7.3. Monoclonal Antibodies
9.7.4. Insulin
9.7.5. Interferon
9.7.6. Granulocyte-Colony Stimulating Factor
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America G-CSF Biosimilars Demand Share Forecast, 2019-2029
10. Latin America G-CSF Biosimilars Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America G-CSF Biosimilars Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America G-CSF Biosimilars Market Size and Volume Forecast by Application
10.4.1. Blood Disorders
10.4.2. Oncology Diseases
10.4.3. Chronic And Autoimmune Diseases
10.4.4. Growth Hormone Deficiencies
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America G-CSF Biosimilars Market Size and Volume Forecast by Type
10.7.1. Human Growth Hormone
10.7.2. Erythropoietin
10.7.3. Monoclonal Antibodies
10.7.4. Insulin
10.7.5. Interferon
10.7.6. Granulocyte-Colony Stimulating Factor
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America G-CSF Biosimilars Demand Share Forecast, 2019-2029
11. Europe G-CSF Biosimilars Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe G-CSF Biosimilars Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe G-CSF Biosimilars Market Size and Volume Forecast by Application
11.4.1. Blood Disorders
11.4.2. Oncology Diseases
11.4.3. Chronic And Autoimmune Diseases
11.4.4. Growth Hormone Deficiencies
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe G-CSF Biosimilars Market Size and Volume Forecast by Type
11.7.1. Human Growth Hormone
11.7.2. Erythropoietin
11.7.3. Monoclonal Antibodies
11.7.4. Insulin
11.7.5. Interferon
11.7.6. Granulocyte-Colony Stimulating Factor
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe G-CSF Biosimilars Demand Share, 2019-2029
12. Asia Pacific G-CSF Biosimilars Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific G-CSF Biosimilars Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific G-CSF Biosimilars Market Size and Volume Forecast by Application
12.4.1. Blood Disorders
12.4.2. Oncology Diseases
12.4.3. Chronic And Autoimmune Diseases
12.4.4. Growth Hormone Deficiencies
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific G-CSF Biosimilars Market Size and Volume Forecast by Type
12.7.1. Human Growth Hormone
12.7.2. Erythropoietin
12.7.3. Monoclonal Antibodies
12.7.4. Insulin
12.7.5. Interferon
12.7.6. Granulocyte-Colony Stimulating Factor
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific G-CSF Biosimilars Demand Share, 2019-2029
13. Middle East & Africa G-CSF Biosimilars Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa G-CSF Biosimilars Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa G-CSF Biosimilars Market Size and Volume Forecast by Application
13.4.1. Blood Disorders
13.4.2. Oncology Diseases
13.4.3. Chronic And Autoimmune Diseases
13.4.4. Growth Hormone Deficiencies
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa G-CSF Biosimilars Market Size and Volume Forecast by Type
13.7.1. Human Growth Hormone
13.7.2. Erythropoietin
13.7.3. Monoclonal Antibodies
13.7.4. Insulin
13.7.5. Interferon
13.7.6. Granulocyte-Colony Stimulating Factor
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa G-CSF Biosimilars Demand Share, 2019-2029
14. Competition Landscape
14.1. Global G-CSF Biosimilars Market: Market Share Analysis
14.2. G-CSF Biosimilars Distributors and Customers
14.3. G-CSF Biosimilars Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Pfizer
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Novartis
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Roche
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Merck & Co.
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Sanofi
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Johnson & Johnson
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Gilead Science
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. GlaxoSmithKline
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. AbbVie
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Amgen
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. AstraZeneca
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Bayer
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
